BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Oct. 23, 2013
View Archived Issues
Pfizer's IMA-638 does not meet endpoints in phase IIa trial
Read More
Updated immunological results published from phase I evaluation of AE37 prostate cancer vaccine
Read More
Antibody DCBPR-01101 targets globo H for breast cancer treatment
Read More
Immunology data reported from phase IIb AllerT vaccine birch pollen allergy study
Read More
FDA approves subcutaneous formulation of Actemra for rheumatoid arthritis
Read More
Oxygen Biotherapeutics to complete development of levosimendan for fast track indication
Read More
AstraZeneca commences phase III program for selumetinib in NSCLC
Read More
Shionogi & Co. patents novel TRPV4 antagonists for pain
Read More
New EGFR inhibitors divulged by Chinese researchers
Read More
R-Pharm CJSC prepares new fusion proteins that bind to RANKL
Read More
Polaris submits IND application to begin phase I trials of ADI-PEG-20 in breast cancer
Read More
Novel coagulation factor Xa inhibitors synthesized at SciFluor Life Sciences
Read More
TherapeuticsMD's TX-12-004-HR estradiol VagiCap shown to improve objective measures of VVA
Read More
FDA grants orphan drug designation to Aduro's immunotherapy for pancreatic cancer
Read More
Phase I study evaluates Debio-0932 plus everolimus for advanced RCC
Read More
New model of Parkinson's disease created with proteasome inhibitor injection
Read More
Chemilia presents a new microtubule targeting/vascular disrupting agent
Read More
AstraZeneca to begin phase I study of AZD-6738
Read More
New PARP6 inhibitors identified for ovarian and breast cancer
Read More
Medivation and Astellas' phase III trial of enzalutamide in prostate cancer meets primary endpoints
Read More
Ferring initiates two phase III trials of infertility treatment candidate FE-999049
Read More
Amgen acquires Roche's rights to filgrastim and pegfilgrastim
Read More
Biocartis licenses test for colon cancer biomarker from Hospital del Mar
Read More
Cubist files NDA for tedizolid for treatment of serious skin infections
Read More
European approval of Gentium's Defitelio for severe veno-occlusive disease
Read More
Thomson Reuters and Orion Bionetworks to develop predictive models for multiple sclerosis
Read More